Format

Send to:

Choose Destination
See comment in PubMed Commons below
Immunotherapy. 2010 Jan;2(1):37-56. doi: 10.2217/imt.09.43.

Directing dendritic cell immunotherapy towards successful cancer treatment.

Author information

  • 1New York University School of Medicine, NYU Langone Medical Center Cancer Institute, 550 First Avenue SML 1303, New York, NY 10016, USA. rachel.sabado@nyumc.org

Abstract

The use of dendritic cells (DCs) for tumor immunotherapy represents a powerful approach for harnessing the patient's own immune system to eliminate tumor cells. However, suboptimal conditions for generating potent immunostimulatory DCs, as well as the induction of tolerance and suppression mediated by the tumors and its microenvironment have contributed to limited success. Combining DC vaccines with new approaches that enhance immunogenicity and overcome the regulatory mechanisms underlying peripheral tolerance may be the key to achieving effective and durable anti-tumor immune responses that translate to better clinical outcomes.

KEYWORDS:

dendritic cell; tumor immunotherapy; vaccination

PMID:
20473346
[PubMed - indexed for MEDLINE]
PMCID:
PMC2867472
Free PMC Article
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Icon for Atypon Icon for PubMed Central
    Loading ...
    Write to the Help Desk